ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.
- Record quarterly sales of $211k, up 50% from prior quarter
- Annual sales surged 88% to $510k in FY26
- New distribution agreements in Malaysia, Hong Kong, and Indonesia
- NervAlign Nerve Guide Matrix advances to Stage 3 towards FDA submission
- Expanded Empliq manufacturing capacity with second approved partner
Record Sales Quarter Signals Commercial Momentum
ReNerve Limited (ASX:RNV) has posted its largest sales quarter to date, reaching $211,000 in revenue for Q4 FY26, a 50% jump from the previous quarter. Full-year sales climbed 88% to $510,000, underscoring growing traction for its peripheral nerve repair products. Customer cash receipts of $189,000 further affirm the company’s accelerating commercial momentum.
Strategic Expansion Across Asia-Pacific Markets
The company has been actively broadening its footprint in key Asia-Pacific territories. Distribution partnerships were inked with Swedish Trading Company for Hong Kong, Macau, and the Greater Bay Area, covering a population of approximately 88 million. Meanwhile, UG Medical was appointed as the commercial partner in Malaysia, following regulatory clearance earlier this year. These agreements set the stage for product launches and market penetration in regions with significant clinical demand.
Adding to this regional push, ReNerve secured marketing approval for its flagship NervAlign Nerve Cuff in Indonesia after quarter-end, opening access to Southeast Asia’s largest healthcare market with over 280 million people. This approval complements existing presence in the US, New Zealand, Hong Kong, Thailand, and Malaysia, reinforcing the company’s strategy to target high-potential nerve repair markets across the Asia-Pacific.
Progress on NervAlign Nerve Guide Matrix Development
On the product development front, ReNerve advanced its NervAlign Nerve Guide Matrix to Stage 3 of a four-stage commercialisation process. This milestone involves manufacturing verification and production of material for formal preclinical testing, packaging, and final product manufacture, with completion targeted by the end of 2026. The Guide Matrix aims to provide a ready-to-use alternative to donor nerve grafts, potentially reducing the need for nerve harvesting in patients.
The company continues to engage with the FDA to align future testing with regulatory expectations, with Stage 4 planned to focus on final production and marketing submissions.
Scaling Manufacturing to Meet Demand for Empliq Range
To support rising demand for its Empliq product range, ReNerve appointed J4 Biologics, a Texas-based human tissue processor, as a second approved manufacturer. This dual-supplier strategy is designed to enhance supply chain resilience, increase production capacity, and reduce lead times. The agreement includes minimum purchase commitments and flexible scaling but is not expected to materially impact near-term financials.
Financial Position and Funding Facility
ReNerve ended the quarter with $1.488 million in cash, bolstered by a $5 million funding facility secured from Riverfort in early July. This facility, backed by future R&D tax rebates, provides staged funding over three years to support commercialisation, product development, and operational expenses. The company’s operating cash flows reflected increased R&D investment, particularly in the Nerve Guide Matrix program, alongside ongoing commercial expansion efforts.
ReNerve’s CEO Dr Julian Chick highlighted the quarter as evidence of the company’s commercial strategy gaining traction, with multiple products contributing to revenue growth and an expanding customer base.
Bottom Line?
ReNerve’s record sales and strategic Asia-Pacific partnerships position it well for growth, but the pace of FDA approvals and market uptake in new regions will be key to watch.
Questions in the middle?
- How swiftly will the NervAlign Nerve Guide Matrix progress through final FDA submission and approval?
- What impact will expanded manufacturing capacity have on Empliq product availability and sales growth?
- How effectively can ReNerve convert its new Asia-Pacific approvals into sustained revenue streams?